high dose cytarabine — Competitive Intelligence Brief

high dose cytarabine (high dose cytarabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog antimetabolite. Area: Oncology.

phase 3 Nucleoside analog antimetabolite DNA synthesis (cytidine analog) Oncology Small molecule

Target snapshot

high dose cytarabine (high dose cytarabine) — International Extranodal Lymphoma Study Group (IELSG). High-dose cytarabine is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA, leading to cell death in rapidly dividing cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
high dose cytarabine TARGET	high dose cytarabine	International Extranodal Lymphoma Study Group (IELSG)	phase 3	Nucleoside analog antimetabolite	DNA synthesis (cytidine analog)
Gemcitabine Injectable Product	Gemcitabine Injectable Product	Henan Cancer Hospital	marketed	Nucleoside analog antimetabolite	Ribonucleotide reductase; DNA incorporation
AraC	AraC	University of California, San Diego	marketed	Nucleoside analog antimetabolite	DNA polymerase; deoxycytidine kinase
standard dose ARA-C	standard dose ARA-C	National Research Center for Hematology, Russia	marketed	Nucleoside analog antimetabolite	DNA polymerase; ribonucleotide reductase
Cytosine Arabinoside	Cytosine Arabinoside	University of Rochester	marketed	Nucleoside analog antimetabolite	DNA polymerase; incorporated into DNA
Cytosin-Arabinosid	Cytosin-Arabinosid	University of Ulm	phase 3	Nucleoside analog antimetabolite	DNA polymerase; cytidine metabolism
Gemcitabine alone	Gemcitabine alone	Intergroupe Francophone de Cancerologie Thoracique	phase 3	Nucleoside analog antimetabolite	Ribonucleotide reductase; DNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog antimetabolite class)

1. Henan Cancer Hospital · 1 drug in this class
2. Intergroupe Francophone de Cancerologie Thoracique · 1 drug in this class
3. International Extranodal Lymphoma Study Group (IELSG) · 1 drug in this class
4. National Research Center for Hematology, Russia · 1 drug in this class
5. University of California, San Diego · 1 drug in this class
6. University of Rochester · 1 drug in this class
7. University of Ulm · 1 drug in this class